Plenary Programme

Monday 27 May

METABOLIC DYSFUNCTION IN CARDIOVASCULAR DISEASE

Manipulating adaptive immunity to curb atherosclerosis
Klaus Ley, La Jolla, USA
Lipids, lipases and fatty liver disease
Helen Hobbs, Dallas, USA
Angiogenesis Revisited: Role and (Therapeutic) Implications of Endothelial Metabolism
Peter Carmeliet, Leuven, Belgium
Cardiovascular aging and mitochondia function
Douglas R. Seals, Boulder, USA

Tuesday 28 May

PREVENTING CVD RISK: WHERE DO WE STAND?

Biomarkers predicting CVD
Chris Packard, Glasgow, UK
The genetic burden in CVD
Heribert Schunkert, Munich, Germany
Estimating risk: What's new?
Ian Graham, Dublin, Ireland
Thomas Lüscher, Zurich, Switzerland
Kausik Ray, London, UK

Wednesday 29 May

LOOKING TO THE FUTURE - NOVEL TREATMENT STRATEGIES

The immune system: The next game-changer?
Matthias Nahrendorf, Boston, USA
System-level analyses of inflammatory and repair macrophages reveal an integrated circuitry of lipid and epigenomic changes
Laszlo Nagy, Florida, USA
New lipid drugs: Is LDL done, ready for new targets?
Erik S. Stroes, Amsterdam, The Netherlands
The HDL story: time to reconsider?
M. John Chapman, Paris, France